Business (Health)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Deals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Deals
Over The Counter 20 March 2023: The Shape Of The Global OTC Market To Come, With IQVIA Consumer Health's Amit Shukla
In this episode, HBW Insight catches up with IQVIA Consumer Health’s vice president of global consulting services, Amit Shukla, to find out how the global consumer healthcare market is performing as it comes out of the pandemic. It’s good news, Shukla reveals, based on the firm’s latest intelligence. The market grew double digits in 2022 and is predicted to expand by 5-6% per year in the future - even faster if some of the innovative switches currently in the pipeline succeed. Shukla points to artificial intelligence, sustainability and popular wellness ingredients as trends to watch that will drive future market growth.
Futura Launches Eroxon Erectile Dysfunction Gel In Europe, US Launch Delayed Until Q2 2023
European consumers can now buy Futura Medical's Eroxon erectile dysfunction gel without a prescription online, and in person via Belgian pharmacies. Further country launches, supported by advertising and promotional campaigns, remain on track during the coming months, Futura says. However, the US launch, expected for Q1 this year, has been delayed while the firm answers questions posed by the FDA.
Reaching 'Transformation' In Turnaround Phase 1, Perrigo Looks To Build On Its Accomplishments
Day after releasing Q4 and full-year results, Perrigo announced launch of next chapter in its “3/5/7” makeover strategy. It reached annual growth of 3% for top line revenues in phase 1, aims for 5% operating income and 7% earnings per share growth in phase 2.
Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Business Strategies
US OTC Monograph Drug Facility Fees Up 8%, Higher Price Tags Stuck On OMORs, Too
FY2023 OTC monograph user fee target facility fee revenue is $25.4m from manufacturers’ fees of $26,153 and contract manufacturers’ fees of $17,435, all due by 1 June. OMOR fees are $517,381 for Tier 1 requests and $103,476 for Tier 2.
People On The Move: Appointments At GSCF, Bayer, Shop Apotheke
A round-up of the latest appointments in the consumer health industry: the Global Self-Care Federation elects J&J's Raghunandanan as its chair; Bayer Consumer Health makes changes to its medical leadership; and Shop Apotheke hires ex-DocMorris CEO to lead company.
Haleon’s Tess Player: Digital Self-Care Can Reduce Health Inequality And Raise Productivity
Haleon's partnership with Microsoft to include 1,500 of the former's products in the latter's Seeing AI application – which reads aloud information on packs for the visually impaired – is an example of how digitalization can help to make healthcare more inclusive, according to vice president and global head of healthcare professionals and health influencer marketing Tess Player.
Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Sales & Earnings
Reaching 'Transformation' In Turnaround Phase 1, Perrigo Looks To Build On Its Accomplishments
Day after releasing Q4 and full-year results, Perrigo announced launch of next chapter in its “3/5/7” makeover strategy. It reached annual growth of 3% for top line revenues in phase 1, aims for 5% operating income and 7% earnings per share growth in phase 2.
Double-Digit Power Brand Growth Helps Haleon Beat Guidance In 2022
The growth of its nine power brands helped Haleon outstrip its sales guidance in 2022. While operating profit also improved, the firm was unable to hit its margin guidance, a miss it blamed on adverse transactional foreign currency.
Reckitt Records Impairment Charge For Biofreeze
Reckitt recorded a £152m impairment charge for Biofreeze in 2022 after the topical pain relief brand underperformed in the first half of the year. Despite issues for Biofreeze, Reckitt's Health business as a whole had a strong showing over the 12 months, with sales jumping by 19%.
Litigation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Legal Issues
California Prop 65 Complaints Against OTC Generics? Ranitidine Could Be First And Last Target
Marketers of copies of national brand OTCs are required under FDA regulations to use the same labeling as the brand, a rule that in effect has limited complaints in California state court alleging Prop 65 violations with nonprescription drug labeling to targeting branded product marketers.
Federal Preemption Strikes California Prop 65 Complaint Against Generic OTC Ranitidine Firms
Whether California court finds Zantac, when marketed containing ranitidine, should have had a Prop 65 label warning could be influenced by dismissal in federal court of class action complaints due to faulty research behind claims that ranitidine causes a carcinogenic substance to form post-production.
EUA For First At-Home Kit Differentiating COVID-19 From Flu Could Be Difference In Firm’s Survival
Sales authorized for first test providing at-home results including differentiating flu from COVID. Lucira gets EUA for its COVID-19 & Flu Test two days after filing for Chapter 11 bankruptcy protection, indicating it would seek buyer.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.